The Life Sciences team represented OncoC4, Inc. in the recent closing of a Series B financing round of nearly $50 million. The round was led by GBA Fund, and supported by additional capital from the Company's co-founders and existing investors, including HM Capital, 3E Bioventures Capital and Kaitai Capital.
Based in Rockville, Maryland, OncoC4 is a clinical-stage biotechnology company that is actively engaged in the discovery and development of novel biologics for the potential treatment of cancer and neurodegenerative disease. OncoC4's pipeline features assets with first-in-class and best-in-class potential targeting both novel and well validated targets across oncology and immunological diseases.
The Goodwin deal team was led by Ben Marsh, Carson Williams, Madison Clausius, and Emma Liberman, with valuable input from Adam Bellack, Ingram Cheung, and Will Wang.
For more information on the deal, please read the press release.